| HSPC-sparing treatment for RB-positive aberrant cell proliferation |
2023-3-20 |
2023-6-06 |
|
| Morphic forms of GIT38 and methods of manufacture thereof |
2022-12-01 |
2023-2-02 |
|
| Cyclin-dependent kinase inhibiting compounds for the treatment of medical … |
2022-11-16 |
2023-1-01 |
|
| Improved treatments for advanced/metastatic cancers with checkpoint inhibitor … |
2022-8-30 |
2023-3-09 |
|
| Anti-neoplastic combinations and dosing regimens using cdk4/6 inhibitor … |
2022-8-29 |
2023-8-03 |
|
| Highly active anti-neoplastic and anti-proliferative agents |
2022-8-17 |
2023-8-10 |
|
| Combination treatments in patients with advanced and/or metastatic trop-2 … |
2022-7-01 |
2023-1-05 |
|
| Treatment of EGFR-Driven Cancer with Fewer Side Effects |
2022-6-30 |
2023-5-11 |
|
| G1t38 superior dosage regimes |
2022-6-13 |
2023-5-18 |
|
| Preservation of immune response during chemotherapy regimens |
2022-6-03 |
2022-8-09 |
|
| Combination therapy for the treatment of cancer |
2022-5-25 |
2022-6-16 |
|
| Targeted treatment of cancers with dysregulated fibroblast growth factor … |
2022-4-11 |
2022-8-04 |
|
| Patient selection for enhancement of anti-tumor immunity in cancer patients |
2021-12-17 |
2022-6-09 |
|
| Treatments for advanced and/or metastatic triple negative breast cancer |
2021-12-09 |
2022-6-16 |
|
| Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
2021-11-03 |
2021-12-02 |
|
| Improved fluorouracil-based multi-agent chemotherapy for treatment of … |
2021-10-19 |
2022-4-28 |
|
| Treatment of rb-negative tumors using topoisomerase inhibitors in combination … |
2021-8-16 |
2022-6-09 |
|
| Morphic forms of trilaciclib and methods of manufacture thereof |
2021-6-15 |
2022-4-16 |
|
| Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/ … |
2021-5-07 |
2021-9-02 |
|
| Morphic forms of trilaciclib and methods of manufacture thereof |
2021-4-21 |
2021-12-16 |
|
| Synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
2021-2-24 |
2021-6-17 |
|
| Benzothiophene estrogen receptor modulators to treat medical disorders |
2021-2-16 |
2021-6-10 |
|
| Cdk inhibitors |
2021-1-20 |
2021-12-23 |
|
| Transient protection of hematopoietic stem and progenitor cells against … |
2020-11-23 |
2021-3-18 |
|
| Treatment of cancers having driving oncogenic mutations |
2020-11-03 |
2021-7-19 |
|
| Pyrimidine-based antiproliferative agents |
2020-11-03 |
2021-2-18 |
|
| Heterocyclic compounds for the treatment of abnormal cellular proliferation |
2020-7-01 |
2020-10-22 |
|
| MEANS TO IMPROVE ANTI-TUMOR IMMUNITY IN CANCER PATIENTS |
2020-6-18 |
2021-12-01 |
|
| Antiproliferative pyrimidine-based compounds |
2020-5-18 |
2020-9-10 |
|
| CDK Inhibitors |
2020-5-07 |
2020-5-28 |
|
| Pyrimidine-based compounds for the treatment of cancer |
2020-4-13 |
2020-7-30 |
|
| Treatment of cdk4/6 inhibitor resistant neoplastic disorders |
2020-4-01 |
2020-10-08 |
|
| Cell cycle inhibiting compounds for the treatment of medical disorders |
2020-4-01 |
2020-10-08 |
|
| Benzothiophene estrogen receptor modulators |
2020-3-19 |
2020-7-09 |
|
| Treatment of EGFR-driven cancer with fewer side effects |
2019-8-21 |
2022-7-26 |
2022-7-26 |
| Cdk inhibitors for the treatment of neoplastic disorders |
2019-5-16 |
2019-11-21 |
|
| Synthesis of lactams |
2018-10-02 |
2021-1-31 |
|
| BENZOTIOPHENES MODULATORS OF STEROGEN RECEPTORS |
2018-2-09 |
2019-5-22 |
|
| Lactam kinase inhibitors |
2018-1-02 |
2018-5-10 |
|
| Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal … |
2017-7-31 |
2019-8-13 |
2019-8-13 |
| Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem … |
2016-2-03 |
2016-8-11 |
|
| Protection of renal tissues from ischemia through inhibition of the … |
2011-11-17 |
2015-2-25 |
|